{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:41:03Z","timestamp":1787240463100,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11864-001-0029-1","type":"journal-article","created":{"date-parts":[[2007,7,4]],"date-time":"2007-07-04T16:32:53Z","timestamp":1183566773000},"page":"355-364","source":"Crossref","is-referenced-by-count":12,"title":["Adrenal cortical carcinoma"],"prefix":"10.1007","volume":"2","author":[{"given":"Robin P.","family":"Boushey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P. B.","family":"Dackiw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"29_CR1","unstructured":"Norton JA. Adrenal tumors. In Cancer: Principles and Practice of Oncology edn 5. Edited by DeVita V, Hellman S, Rosenberg D. Philadelphia: Lippincott-Raven Publishers, 1997:1659."},{"key":"29_CR2","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N","volume":"72","author":"MD Wooten","year":"1993","unstructured":"Wooten MD, King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993, 72:3145\u20133155.","journal-title":"Cancer"},{"key":"29_CR3","first-page":"972","volume":"112","author":"P Icard","year":"1992","unstructured":"Icard P, Chapuis Y, Andreassian B, et al.:Adrenal cortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French association of endocrine surgery. Surgery 1992, 112:972\u2013979.","journal-title":"Surgery"},{"key":"29_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1067\/msy.1998.92009","volume":"124","author":"JE Lee","year":"1998","unstructured":"Lee JE, Evans DB, Hickey RC, et al.: Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 1998, 124:1115\u20131122. Paper from a center experienced in the management of patients with adrenal cortical cancer and adrenal masses.","journal-title":"Surgery"},{"key":"29_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199011153232007","volume":"323","author":"NS Ross","year":"1990","unstructured":"Ross NS, Aron DC: Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990, 323:1401\u20131405.","journal-title":"N Engl J Med"},{"key":"29_CR6","first-page":"1018","volume":"102","author":"JL Doppman","year":"1987","unstructured":"Doppman JL, Reinig JW, Dwyer AJ, et al.: Differentiation of adrenal masses by magnetic resonance imaging. Surgery 1987, 102:1018\u20131026.","journal-title":"Surgery"},{"key":"29_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s004649900892","volume":"13","author":"SR Schell","year":"1999","unstructured":"Schell SR, Talamini MA, Udelsman R: Laparoscopic adrenalectomy for nonmalignant disease: improved safety, morbidity, and cost-effectiveness. Surg Endosc 1999, 13:30\u201334.","journal-title":"Surg Endosc"},{"key":"29_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s004320000170","volume":"127","author":"D Kopf","year":"2001","unstructured":"Kopf D, Goretzki PE, Lehnert H: Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001, 127:143\u2013155. Recent review of adrenal tumor management.","journal-title":"J Cancer Res Clin Oncol"},{"key":"29_CR9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bjc.1994.183","volume":"69","author":"HR Haak","year":"1994","unstructured":"Haak HR, Hermans J, van de Velde CJ, et al.: Optimal treatment of adrenal cortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994, 69:947\u2013951.","journal-title":"Br J Cancer"},{"key":"29_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","volume":"322","author":"JP Luton","year":"1990","unstructured":"Luton JP, Cerdas S, Billaud L, et al.: Clinical features of adrenal cortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322:1195\u20131201.","journal-title":"N Engl J Med"},{"key":"29_CR11","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1002\/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8","volume":"71","author":"R Vassilopoulou-Sellin","year":"1993","unstructured":"Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al.: Impact of adjuvant mitotane on the clinical course of patients with adrenal cortical cancer. Cancer 1993, 71:3119\u20133123.","journal-title":"Cancer"},{"key":"29_CR12","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1002\/1097-0142(19950515)75:10<2587::AID-CNCR2820751028>3.0.CO;2-5","volume":"75","author":"AA Kasperlik-Zaluska","year":"1995","unstructured":"Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, et al.: Adrenal cortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995, 75:2587\u20132591.","journal-title":"Cancer"},{"key":"29_CR13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bjc.1998.530","volume":"78","author":"R Bonacci","year":"1998","unstructured":"Bonacci R, Gigliotti A, Baudin E, et al.: Cytotoxic therapy with etoposide and cisplatin in advanced adrenal cortical carcinoma. Reseau comete inserm. Br J Cancer 1998, 78:546\u2013549.","journal-title":"Br J Cancer"},{"key":"29_CR14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF03345807","volume":"15","author":"M Schlumberger","year":"1992","unstructured":"Schlumberger M, Gicquel C, Lumbroso J, et al.: Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992, 15:631\u2013642.","journal-title":"J Endocrinol Invest"},{"key":"29_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1210\/jcem-73-1-18","volume":"73","author":"SE Bates","year":"1991","unstructured":"Bates SE, Shieh CY, Mickley LA, et al.: Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1\/p-glycoprotein) which is also expressed by adrenal cortical carcinomas. J Clin Endocrinol Metab 1991, 73:18\u201329.","journal-title":"J Clin Endocrinol Metab"},{"key":"29_CR16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/030089169207800512","volume":"78","author":"A Berruti","year":"1992","unstructured":"Berruti A, Terzolo M, Paccotti P, et al.: Favorable response of metastatic adrenal cortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. Tumori 1992, 78:345\u2013348.","journal-title":"Tumori"},{"key":"29_CR17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/pgmj.75.880.96","volume":"75","author":"NN Chan","year":"1999","unstructured":"Chan NN, Isaacs AJ: Lack of response to octreotide in Cushing\u2019s syndrome due to metastatic adrenal cortical carcinoma. Postgrad Med J 1999, 75:96\u201397.","journal-title":"Postgrad Med J"},{"key":"29_CR18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2265.1994.tb02549.x","volume":"41","author":"W Arlt","year":"1994","unstructured":"Arlt W, Reincke M, Siekmann L, et al.: Suramin in adrenal cortical cancer: Limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 1994, 41:299\u2013307.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"29_CR19","first-page":"3754","volume":"49","author":"YW Wu","year":"1989","unstructured":"Wu YW, Chik CL, Knazek RA: An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenal cortical carcinoma. Cancer Res 1989, 49:3754\u20133758.","journal-title":"Cancer Res"},{"key":"29_CR20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/07435809609043766","volume":"22","author":"F Fallo","year":"1996","unstructured":"Fallo F, Pilon C, Barzon L, et al.: Effects of taxol on the human NCI-H295 adrenal cortical carcinoma cell line. Endocrinol Res 1996, 22:709\u2013715.","journal-title":"Endocrinol Res"},{"key":"29_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0960-0760(94)90267-4","volume":"49","author":"D Engelhardt","year":"1994","unstructured":"Engelhardt D, Weber MM: Therapy of Cushing\u2019s syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994, 49:261\u2013267.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"29_CR22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/acta.0.1090451","volume":"109","author":"M Thoren","year":"1985","unstructured":"Thoren M, Adamson U, Sjoberg HE: Aminoglutethimide and metyrapone in the management of Cushing\u2019s syndrome. Acta Endocrinol (Copenh) 1985, 109:451\u2013457.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"29_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1001\/archsurg.134.2.181","volume":"134","author":"LE","year":"1999","unstructured":"Harrison|LE, Gaudin PB, Brennan MF: Pathologic features of prognostic significance for adrenal cortical carcinoma after curative resection. Arch Surg 1999, 134:181\u2013185. Tumor diameter greater than 12 cm, six or more mitotic figures per 10 high-power fields, and the presence of histologic evidence of intratumoral hemorrhage were found to predict short survival in this series of patients from another experienced center.","journal-title":"Arch Surg"},{"key":"29_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s002689900442","volume":"22","author":"A Khorram-Manesh","year":"1998","unstructured":"Khorram-Manesh A, Ahlman H, Jansson S, et al.: Adrenal cortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998, 22:605\u2013611.","journal-title":"World J Surg"},{"key":"29_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0039-6060(96)80164-4","volume":"119","author":"F Crucitti","year":"1996","unstructured":"Crucitti F, Bellantone R, Ferrante A, et al.: The Italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119:161\u2013170.","journal-title":"Surgery"},{"key":"29_CR26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0039-6060(05)80119-9","volume":"118","author":"JE","year":"1995","unstructured":"Lee|JE, Berger DH, el-Naggar AK, et al.: Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995, 118:1090\u20131098. This paper emphasizes the importance of marginnegative resection in the management of patients with adrenal cortical carcinoma.","journal-title":"Surgery"},{"key":"29_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/jso.2930550306","volume":"55","author":"GC Zografos","year":"1994","unstructured":"Zografos GC, Driscoll DL, Karakousis CP, et al.: Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 1994, 55:160\u2013164.","journal-title":"J Surg Oncol"},{"key":"29_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/BF02067377","volume":"16","author":"P Icard","year":"1992","unstructured":"Icard P, Louvel A, Chapuis Y: Survival rates and prognostic factors in adrenal cortical carcinoma. World J Surg 1992, 16:753\u2013758.","journal-title":"World J Surg"},{"key":"29_CR29","first-page":"963","volume":"112","author":"RF Pommier","year":"1992","unstructured":"Pommier RF, Brennan MF: An eleven-year experience with adrenal cortical carcinoma. Surgery 1992, 112:963\u2013970.","journal-title":"Surgery"},{"key":"29_CR30","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/BF02067349","volume":"16","author":"JA Soreide","year":"1992","unstructured":"Soreide JA, Brabrand K, Thoresen SO: Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992, 16:663\u2013667.","journal-title":"World J Surg"},{"key":"29_CR31","first-page":"500","volume":"16","author":"S Gr\u00f6ndal","year":"1990","unstructured":"Gr\u00f6ndal S, Cedermark B, Eriksson B, et al.: Adrenal cortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990, 16:500\u2013506.","journal-title":"Eur J Surg Oncol"},{"key":"29_CR32","first-page":"926","volume":"94","author":"DJ Henley","year":"1983","unstructured":"Henley DJ, van Heerden JA, Grant CS, et al.: Adrenal cortical carcinoma\u2014a continuing challenge. Surgery 1983, 94:926\u2013931.","journal-title":"Surgery"},{"key":"29_CR33","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0022-5347(17)57317-6","volume":"120","author":"M Sullivan","year":"1978","unstructured":"Sullivan M, Boileau M, Hodges CV: Adrenal cortical carcinoma. J Urol 1978, 120:660\u2013665.","journal-title":"J Urol"},{"key":"29_CR34","first-page":"155","volume":"23","author":"DA MacFarlane","year":"1958","unstructured":"MacFarlane DA: Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958, 23:155\u2013186.","journal-title":"Ann R Coll Surg Engl"},{"key":"29_CR35","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/1097-0142(19890801)64:3<765::AID-CNCR2820640333>3.0.CO;2-I","volume":"64","author":"S Venkatesh","year":"1989","unstructured":"Venkatesh S, Hickey RC, Sellin RV, et al.: Adrenal cortical carcinoma. Cancer 1989, 64:765\u2013769.","journal-title":"Cancer"},{"key":"29_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jso.2930290208","volume":"29","author":"CP Karakousis","year":"1985","unstructured":"Karakousis CP, Rao U, Moore R: Adrenal adenocarcinomas: histologic grading and survival. J Surg Oncol 1985, 29:105\u2013111.","journal-title":"J Surg Oncol"},{"key":"29_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0277-5379(84)90033-6","volume":"20","author":"H van Slooten","year":"1984","unstructured":"van Slooten H, Moolenaar AJ, van Seters AP, et al.: The treatment of adrenal cortical carcinoma with o,p\u2019-ddd: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984, 20:47\u201353.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"29_CR38","first-page":"191a","volume":"18","author":"S Abraham","year":"1999","unstructured":"Abraham S, Bakke A, Rutt B, et al.: A study of combination chemotherapy and surgical resection in the treatment of adrenal cortical cancer (ACC): continuous infusion doxorubicin, vincristine and etoposide with daily mitotane before and after surgical resection. Proc Am Soc Clin Oncol 1999, 18:191a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"29_CR39","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.3.CO;2-V","volume":"83","author":"A Berruti","year":"1998","unstructured":"Berruti A, Terzolo M, Pia A, et al.: Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenal cortical carcinoma. Italian group for the study of adrenal cancer. Cancer 1998, 83:2194\u20132200.","journal-title":"Cancer"},{"key":"29_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/00000421-199606000-00003","volume":"19","author":"J Zidan","year":"1996","unstructured":"Zidan J, Shpendler M, Robinson E: Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p\u2019ddd. Clinical case reports. Am J Clin Oncol 1996, 19:229\u2013231.","journal-title":"Am J Clin Oncol"},{"key":"29_CR41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.1993.11.1.161","volume":"11","author":"RM Bukowski","year":"1993","unstructured":"Bukowski RM, Wolfe M, Levine HS, et al.: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group Study. J Clin Oncol 1993, 11:161\u2013165.","journal-title":"J Clin Oncol"},{"key":"29_CR42","first-page":"222","volume":"71","author":"PJ Hesketh","year":"1987","unstructured":"Hesketh PJ, McCaffrey RP, Finkel HE, et al.: Cisplatinbased treatment of adrenal cortical carcinoma. Cancer Treat Rep 1987, 71:222\u2013224.","journal-title":"Cancer Treat Rep"},{"key":"29_CR43","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1002\/1097-0142(19861115)58:10<2198::AID-CNCR2820581006>3.0.CO;2-A","volume":"58","author":"DH Johnson","year":"1986","unstructured":"Johnson DH, Greco FA: Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986, 58:2198\u20132202.","journal-title":"Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0029-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-001-0029-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0029-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0029-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T10:22:54Z","timestamp":1652610174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-001-0029-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["29"],"URL":"https:\/\/doi.org\/10.1007\/s11864-001-0029-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}